Overview

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

Status:
Unknown status

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma. For the recurrent population, those patients that do not require immediate surgical resection will be eligible. Patients will be treated with 4 cycles, followed by surgical resection if possible. If indicated, surgery may take place prior to the completion of 4 cycles.

Phase:

Phase 1

Details

Lead Sponsor:

Deric M Park MD

Treatments:

Histone Deacetylase Inhibitors
Imatinib Mesylate
Mitogens
Panobinostat